Interpretation of the Global Tuberculosis Report 2022 by World Health Organization

doi:10.16150/j.1671-2870.2023.01.004

Abstract

Abstract:

Global Tuberculosis Report 2022 (hereafter referred to as “report”), newly published by the World Health Organization (WHO), states that the coronavirus (COVID-19) pandemic has increased the tuberculosis (TB) disease burden and severely affected global TB prevention and control. In 2021, WHO approved a total of six molecular diagnostic technologies for TB diagnosis and anti-TB drug resistance detection, and three new TB antigen-based skin tests for TB screening were recommended. To reduce the burden on patients and the health system, WHO recommends a 4-month regimen for drug-susceptible TB and four shorter regimens for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB). In addition, there were 26 drugs for TB treatment in clinical trials, and at least 22 clinical trials evaluating drugs and drug regimens for TB treatment were underway. In 2021， the TB epidemic remains severe in China, with the number of newly diagnosed cases ranking third among the 30 countries. In 2021, a total of 639 548 TB cases and 1 763 deaths were reported nationwide, with an incidence of 45.37/100 000 and a mortality of 0.13/100 000. China has the fourth largest number of MDR/RR-TB patients in the world. However, it is necessary to verify whether the regimens for MDR/RR-TB treatment recommended by WHO are suitable for patients in China.

Key words: Tuberculosis, Rifampicin resistance, Burden of disease, Epidemiology

CLC Number:

R521

LIANG Chen, YU Jiajia, TANG Shenjie. Interpretation of the Global Tuberculosis Report 2022 by World Health Organization[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(01): 21-30.

Figures/Tables 4

References 49

[1]	World Health Organization. Global tuberculosis report 2022[R/OL]. Geneva: World Health Organization, 2022. https://www.who.int/teams/global-tuberculosis-programme/TB-reports/global-tuberculosis-report-2022.
[2]	DHEDA K, PERUMAL T, MOULTRIE H, et al. The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions[J]. Lancet Respir Med, 2022, 10(6):603-622. doi: 10.1016/S2213-2600(22)00092-3 pmid: 35338841
[3]	World Health Organization. Impact of the COVID-19 pandemic on TB detection and mortality in 2020[R/OL]. Geneva: World Health Organization, 2021. https://www.who.int/publications/m/item/impact-of-the-covid-19-pandemic-on-tb-detection-and-mortality-in-2020.
[4]	梁晨, 唐神结. 临床结核病病原体分子生物学诊断年度进展2022[J]. 中华结核和呼吸杂志, 2023, 46(2):176-182.
	LIANG C, TANG S J. Annual progress on molecular biological diagnosis of tuberculosis 2022[J]. Chin J Tuberc Respir Dis, 2023, 46(2):176-182.
[5]	WHO consolidated guidelines on tuberculosis. Module 3: diagnosis-rapid diagnostics for tuberculosis detection[R/OL]. Geneva: World Health Organization, 2021. https://www.ncbi.nlm.nih.gov/books/NBK572344/.
[6]	WHO consolidated guidelines on tuberculosis. Module 3: diagnosis-rapid diagnostics for tuberculosis detection[R/OL]. Geneva: World Health Organization, 2021. https://www.ncbi.nlm.nih.gov/books/NBK572344/.
[7]	BISWAS S, UDDIN M K M, PAUL K K, et al. Xpert MTB/RIF Ultra assay for the detection of Mycobacterium tuberculosis in people with negative conventional Xpert MTB/RIF but chest imaging suggestive of tuberculosis in Dhaka, Bangladesh[J]. Int J Infect Dis, 2022, 114:244-251. doi: 10.1016/j.ijid.2021.11.010 URL
[8]	PENG X, LIAO Q, FANG M, et al. Detection of pulmonary tuberculosis in children using the Xpert MTB/RIF Ultra assay on sputum: a multicenter study[J]. Eur J Clin Microbiol Infect Dis, 2022, 41(2):235-243. doi: 10.1007/s10096-021-04340-0
[9]	SIGNORINO C, VOTTO M, DE FILIPPO M, et al. Diagnostic accuracy of Xpert ultra for childhood tuberculosis: A preliminary systematic review and meta-analysis[J]. Pediatr Allergy Immunol, 2022, 33(Suppl 27):80-82. doi: 10.1111/pai.v33.s27 URL
[10]	SUN L, LIU Y, FANG M, et al. Use of Xpert MTB/RIF Ultra assay on stool and gastric aspirate samples to diagnose pulmonary tuberculosis in children in a high-tuberculosis-burden but resource-limited area of China[J]. Int J Infect Dis, 2022, 114:236-243. doi: 10.1016/j.ijid.2021.11.012 URL
[11]	BOLOKO L, SCHUTZ C, SIBIYA N, et al. Xpert Ultra testing of blood in severe HIV-associated tuberculosis to detect and measure Mycobacterium tuberculosis blood stream infection: a diagnostic and disease biomarker cohort study[J]. Lancet Microbe, 2022, 3(7):e521-e532. doi: 10.1016/S2666-5247(22)00062-3 URL
[12]	PENN-NICHOLSON A, GOMATHI S N, UGARTE-GIL C, et al. A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays[J]. Eur Respir J, 2021, 58(5):2100526. doi: 10.1183/13993003.00526-2021 URL
[13]	NGANGUE Y R, MBULI C, NEH A, et al. Diagnostic Accuracy of the Truenat MTB Plus Assay and Comparison with the Xpert MTB/RIF Assay to Detect Tuberculosis among Hospital Outpatients in Cameroon[J]. J Clin Microbiol, 2022, 60(8):e0015522. doi: 10.1128/jcm.00155-22 URL
[14]	MEAZA A, TESFAYE E, MOHAMED Z, et al. Diagnostic accuracy of Truenat Tuberculosis and Rifampicin-Resistance assays in Addis Ababa, Ethiopia[J]. PLoS One, 2021, 16(12):e0261084. doi: 10.1371/journal.pone.0261084 URL
[15]	ENGEL N, OCHODO E A, KARANJA P W, et al. Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views[J]. Cochrane Database Syst Rev, 2022, 4(4):CD014877.
[16]	SHARMA K, SHARMA M, SHARMA V, et al. Evalua-ting diagnostic performance of Truenat MTB Plus for gastrointestinal tuberculosis[J]. J Gastroenterol Hepatol, 2022, 37(8):1571-1578. doi: 10.1111/jgh.v37.8 URL
[17]	HUANG Z, LACOURSE S M, KAY A W, et al. CRISPR detection of circulating cell-free Mycobacterium tuberculosis DNA in adults and children, including children with HIV: a molecular diagnostics study[J]. Lancet Microbe, 2022, 3(7):e482-e492. doi: 10.1016/S2666-5247(22)00087-8 URL
[18]	ORESKOVIC A, WAALKES A, HOLMES E A, et al. Characterizing the molecular composition and diagnostic potential of Mycobacterium tuberculosis urinary cell-free DNA using next-generation sequencing[J]. Int J Infect Dis, 2021, 112:330-337. doi: 10.1016/j.ijid.2021.09.042 URL
[19]	ZHENG W, QUAN B, GAO G, et al. Combination of Circulating Cell-Free DNA and Positron Emission Tomography to Distinguish Non-Small Cell Lung Cancer from Tuberculosis[J]. Lab Med, 2023, 54(2):130-141. doi: 10.1093/labmed/lmac085 URL
[20]	DASS M, AITTAN S, MUTHUMOHAN R, et al. Utility of cell-free transrenal DNA for the diagnosis of Tuberculous Meningitis: A proof-of-concept study[J]. Tuberculosis (Edinb), 2022, 135:102213. doi: 10.1016/j.tube.2022.102213 URL
[21]	PARK J H, KOO B, KIM M J, et al. Utility of plasma cell-free DNA detection using homobifunctional imidoesters using a microfluidic system for diagnosing active tuberculosis[J]. Infect Dis (Lond), 2022, 54(1):46-52.
[22]	WU X, TAN G, YANG J, et al. Prediction of Mycobacterium tuberculosis drug resistance by nucleotide MALDI-TOF-MS[J]. Int J Infect Dis, 2022, 121:47-54. doi: 10.1016/j.ijid.2022.04.061 pmid: 35523300
[23]	SHI J, HE G, NING H, et al. Application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in the detection of drug resistance of Mycobacterium tuberculosis in re-treated patients[J]. Tuberculosis (Edinb), 2022, 135:102209. doi: 10.1016/j.tube.2022.102209 URL
[24]	KHAN F A, MAJIDULLA A, TAVAZIVA G, et al. Chest x-ray analysis with deep learning-based software as a triage test for pulmonary tuberculosis: a prospective study of diagnostic accuracy for culture-confirmed disease[J]. Lancet Digit Health, 2020, 2(11):e573-e581.
[25]	TAVAZIVA G, HARRIS M, ABIDI S K, et al. Chest X-ray Analysis With Deep Learning-Based Software as a Triage Test for Pulmonary Tuberculosis: An Individual Patient Data Meta-Analysis of Diagnostic Accuracy[J]. Clin Infect Dis, 2022, 74(8):1390-1400. doi: 10.1093/cid/ciab639 URL
[26]	TAVAZIVA G, MAJIDULLA A, NAZISH A, et al. Diagnostic accuracy of a commercially available, deep lear-ning-based chest X-ray interpretation software for detec-ting culture-confirmed pulmonary tuberculosis[J]. Int J Infect Dis, 2022, 122:15-20. doi: 10.1016/j.ijid.2022.05.037 URL
[27]	WHO. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-susceptible tuberculosis treatment, 2022 update[R/OL]. Geneva: World Health Organization, 2022. https://www.ncbi.nlm.nih.gov/books/NBK581329/.
[28]	DORMAN S E, NAHID P, KURBATOVA E V, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis[J]. N Engl J Med, 2021, 384(18):1705-1718. doi: 10.1056/NEJMoa2033400 URL
[29]	TURKOVA A, WILLS GH, WOBUDEYA E, et al. Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children[J]. N Engl J Med, 2022, 386(10):911-922. doi: 10.1056/NEJMoa2104535 URL
[30]	World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis[M]. Geneva: World Health Organization, 2022.
[31]	WHO. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update[R/OL]. Geneva: WHO, 2022. https://www.ncbi.nlm.nih.gov/books/NBK558570/.
[32]	黄小艺, 刘志伟. 妇幼保健院新生儿早发型血流感染分析[J]. 中华医院感染学杂志, 2012, 22(11):2329-2332.
	HUANG X Y, LIU Z W. Analysis of neonatal early-onset blood stream infections in maternal and children's hospital[J]. Chin J Nosocomiol, 2012, 22(11):2329-2332.
[33]	KIM J S, KIM Y H, LEE S H, et al. Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis[J]. Antimicrob Agents Chemother, 2022, 66(2):e0168421. doi: 10.1128/aac.01684-21 URL
[34]	BRUINENBERG P, NEDELMAN J, YANG T J, et al. Single Ascending-Dose Study To Evaluate the Safety, To-lerability, and Pharmacokinetics of Sutezolid in Healthy Adult Subjects[J]. Antimicrob Agents Chemother, 2022, 66(4):e0210821. doi: 10.1128/aac.02108-21 URL
[35]	KIM J, CHOI J, KANG H, et al. Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects[J]. Antimicrob Agents Chemother, 2022, 66(1):e0143621. doi: 10.1128/AAC.01436-21 URL
[36]	NASIRI M J, ZANGIABADIAN M, ARABPOUR E, et al. Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis[J]. Int J Infect Dis, 2022, 124(Suppl 1):S90-S103. doi: 10.1016/j.ijid.2022.02.043 URL
[37]	GARCIA-PRATS A J, FRIAS M, VAN DER LAAN L, et al. Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial[J]. Antimicrob Agents Chemother, 2022, 66(5):e0214421. doi: 10.1128/aac.02144-21 URL
[38]	GILS T, LYNEN L, DE JONG B C, et al. Pretomanid for tuberculosis: a systematic review[J]. Clin Microbiol Infect, 2022, 28(1):31-42. doi: 10.1016/j.cmi.2021.08.007 URL
[39]	NDJEKA N, CAMPBELL J R, MEINTJES G, et al. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study[J]. Lancet Infect Dis, 2022, 22(7):1042-1051. doi: 10.1016/S1473-3099(21)00811-2 pmid: 35512718
[40]	ESMAIL A, OELOFSE S, LOMBARD C, et al. An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)[J]. Am J Respir Crit Care Med, 2022, 205(10):1214-1227. doi: 10.1164/rccm.202107-1779OC URL
[41]	DECROO T, AUNG K J M, HOSSAIN M A, et al. Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis[J]. Eur Respir J, 2022, 59(3):2102124. doi: 10.1183/13993003.02124-2021 URL
[42]	HUERGA H, KHAN U, BASTARD M, et al. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs[J]. Clin Infect Dis, 2022, 75(8):1307-1314. doi: 10.1093/cid/ciac176 URL
[43]	KHAN P Y, FRANKE M F, HEWISON C, et al. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings[J]. Eur Respir J, 2022, 59(1):2004345. doi: 10.1183/13993003.04345-2020 URL
[44]	HEWISON C, KHAN U, BASTARD M, et al. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort[J]. Clin Infect Dis, 2022, 75(6):1006-1013. doi: 10.1093/cid/ciac019 pmid: 35028659
[45]	MOHR-HOLLAND E, DANIELS J, REUTER A, et al. Early mortality during rifampicin-resistant TB treatment[J]. Int J Tuberc Lung Dis, 2022, 26(2):150-157. doi: 10.5588/ijtld.21.0494 URL
[46]	MOK J, LEE M, KIM D K, et al. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea[J]. Lancet, 2022, 400(10362):1522-1530. doi: 10.1016/S0140-6736(22)01883-9 pmid: 36522208
[47]	NYANG'WA B T, BERRY C, KAZOUNIS E, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis[J]. N N Engl J Med, 2022, 387(25):2331-2343.
[48]	中华人民共和国国家卫生健康委员会疾病预防控制局. 全国法定传染病疫情概况[R/OL]. (2022-02-01)[2022-04-22]. http://www.nhc.gov.cn/jkj/ne_index.shtml.
	Disease Prevention and Control Bureau of the National Health Commission of the People's Republic of China. Overview of the national epidemic of statutory infectious diseases[R/OL](2022-04-22)[2023-02-01]. http://www.nhc.gov.cn/jkj/ne_index.shtml.
[49]	World Health Organization. Tuberculosis profile: China[R/OL]. 2021-10-27[2022-10-27]. https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22&lan=%22EN%22&iso2=%22CN%22.

项目	里程碑		目标
项目	2020年	2025年	2030年	2035年
因结核病死亡人数下降的百分比（与2015年基线相比）	35%	75%	90%	95%
结核病发病率下降的百分比（与2015年基线相比）	20%	50%	80%	90%
受结核病影响的家庭因结核病而面临灾难性成本的百分比（2015年水平未知）	0	0	0	0

指标	目标
2018年至2022年（5年内）接受治疗的结核病患者例数	4 000万例患者（包括350万儿童)，其中有150万耐药结核病病例（包括115 000例耐药结核病儿童）
2018年至2022年（5年内）接受结核病预防性治疗者例数	至少3 000万人，包括400万名与结核病患者有家庭接触的5岁以下的儿童；2 000万名与结核病患者有家庭接触的老年人；600万例HIV感染者
为普及结核病的高质量预防、诊断、治疗和护理提供年度资金	截至2022年，每年至少130亿美元
结核病研究的年度资助	2018年至2022年这5年内，每年20亿美元

国家	估算发病率/100 000 （95% CI）	估算发病人数 (×1 000 000) （95% CI）	全球份额
印度	210（178~244）	3（2.500~3.400）	28.0%
印度尼西亚	354（318~391）	0.969（0.872~1.100）	9.2%
中国	55（47~63）	0.780（0.665~0.905）	7.4%
菲律宾	650（352~1 000）	0.741（0.401~1.200）	7.0%
巴基斯坦	264（192~347）	0.611（0.445~0.803）	5.8%
尼日利亚	219（143~311）	0.476（0.305~0.664）	4.4%
孟加拉国	221（161~291）	0.375（0.273~0.493）	3.6%
刚果	370（231~542）	0.022（0.013~0.032）	2.9%